Rapamycin Inhibits Glioma Cells Growth and Promotes Autophagy by miR-26a-5p/DAPK1 Axis
Authors Wang Z, Wang X, Cheng F, Wen X, Feng S, Yu F, Tang H, Liu Z, Teng X
Received 23 December 2020
Accepted for publication 25 February 2021
Published 22 March 2021 Volume 2021:13 Pages 2691—2700
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Eileen O'Reilly
Zheng Wang,1,* Xiaoxi Wang,2,* Fei Cheng,2 Xue Wen,2 Shi Feng,2 Fang Yu,2 Hui Tang,2 Zhengjin Liu,3 Xiaodong Teng2
1Department of Neurology, Hangzhou Seventh People’s Hospital, Hangzhou, People’s Republic of China; 2Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 3Department of Pathology, Zhongshan Hospital, Xiamen University, Xiamen, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhengjin Liu
Department of Pathology, Zhongshan Hospital, Xiamen University, 201 Hubin South Road, Xiamen, Fujian, 361004, People’s Republic of China
Email [email protected]
Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310000, People’s Republic of China
Email [email protected]
Background: Glioma is a common intracranial malignant tumor with high rates of invasiveness and mortality. This study aimed to investigate the mechanism of rapamycin in glioma.
Methods: U118-MG cells were treated with and without rapamycin in vivo and then collected for RNA sequencing. Differentially expressed miRNAs (DEMs) were screened and verified. MiR-26a-5p was selected for functional verification, and the target gene of miR-26a-5p was identified. The effects of miR-26a-5p on cell proliferation, cell cycle, apoptosis, and autophagy were also investigated.
Results: In total, 58 up-regulated and 41 down-regulated DEMs were identified between rapamycin-treated and untreated U118-MG cells. MiR-26-5p levels were up-regulated in U118-MG cells treated with 12.5 μM rapamycin, and death-associated protein kinase 1 (DAPK1) expression, a direct miR-26a-5p target gene, was down-regulated. Rapamycin substantially inhibited cell proliferation and cell percentage in the S phase and promoted cell apoptosis; miR-26a-5p inhibitor increased cell proliferation and cell cycle and decreased cell apoptosis; DAPK1 overexpression further induced cell proliferation, increased the cell number in the S phase, and inhibited apoptosis in glioma cells. Notably, rapamycin increased the autophagy-related Beclin1 protein expression levels and the LC3 II/I ratio.
Conclusion: Rapamycin exerts anti-tumor effects by promoting autophagy in glioma cells, which was dependent on the miR-26a-5p/DAPK1 pathway activation by rapamycin.
Keywords: rapamycin, autophagy, RNA sequencing, glioma cells, miR-26a-5p, death-associated protein kinase 1
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]